Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.42
(
-1.23%
)
Bitcoin
74,527.58
(
0.79%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 133476

Wednesday, 12/21/2011 2:15:10 PM

Wednesday, December 21, 2011 2:15:10 PM

Post# of 257253
Clarification on Teva’s 2012 Copaxone forecast: Insofar as Teva’s corporate style does not allow an admission that Teva might lose the patent case, Teva did not qualify its Copaxone forecast according to whether a generic version launches in the US market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now